Clindamycin has been shown to be effective in the treatment of the following infections when caused by susceptible anaerobic bacteria or susceptible strains of gram positive bacteria such as Streptococci, Staphylococci and pneumococci: upper respiratory tract infections, lower respiratory tract infections, skin and soft tissue infections, bone and joint infections, pelvic infections, intra-abdominal infections, septicema and endocarditis, dental infections. As an alternative therapy when used in combination with quinine or amodiaquine for the treatment of multi-drug resistant Plasmodium falciparum infection.
 

Clindamycin is a lincosamide antibiotic. Clindamycin inhibits bacterial protein synthesis by binding to the 50s subunit of the ribosome. It has activity against aerobic gram-positive cocci, including: Staphylococcus aureus, Staphylococcus epidermidis (penicillinase and non-penicillinase producing strains), Streptococci, Pneumococci, anaerobic gram-negative bacilli including: Bacteroides species, Fusobacterium species. Anaerobic gram-positive non-spore forming bacilli including: Propionibacterium species, Eubacterium species, Actinomyces species, anaerobic and microaerophilic gram-positive cocci including: Peptococcus species, Peptostreptococcus species, Microaerophilic streptococci, C. perfringens.

Serious Infections: 150 mg - 300 mg every 6 hours.
More severe infections: 300 mg - 450 mg every 6 hours.
Pediatric Patients
Serious Infections: 8 - 16 mg/kg/day divided into 3 or 4 equal doses.
More severe infections: 16 - 20 mg/kg/day divided into 3 or 4 equal doses.

Clindamycin enhance the action of other neuromuscular blocking agents. Therefore, it should be used with caution in patients receiving such agents. Antagonism has been
demonstrated between Clindamycin and Erythromycin in vitro. Because of possible clinical significance, these two drugs should not be administered concurrently.

Clindamycin is contraindicated in patients previously found to be sensitive to Clindamycin or Lincomycin or any of the ingredients of this medicine.

The adverse effects have been reported with the use of Clindamycin are abdominal pain, oesophagitis and oesophagial ulcer, nausea, vomiting and diarrhea, pruritus, skin rashes and urticaria.

Pregnancy category B: Clindamycin crosses the placenta in humans. After multiple doses, amniotic fluid concentrations were approximately 30% of maternal concentrations. Clindamycin should be used in pregnancy only if clearly needed.
Lactation: Clindamycin has been reported to appear in breast milk. Therefore, it is not recommended for nursing mothers if not clearly needed.

Clindamycin should be prescribed with caution in individuals with a history of gastrointestinal disease, particularly colitis.

Overdosage with orally administered Clindamycin has been rare. Adverse reactions similar to those seen with normal doses can be expected. However, unexpected reactions could occur. Haemodialysis and peritoneal dialysis are not effective in removing Clindamycin from the serum. Overdosage should be treated with simple gastric lavage. No specific antidote is known.

· Store in cool & dry place, protected from light.
· Keep out of reach of children.